olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.
![Olema Pharmaceuticals logo](/files/LOGO/1750284-OLMA.png)
Company profile
Ticker
OLMA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Olema Oncology Australia PTY LTD ...
IRS number
300409740
OLMA stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
2 Jul 24
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
8-K
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
15 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
8 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
Latest ownership filings
4
Cyrus Harmon
12 Jul 24
144
Notice of proposed sale of securities
11 Jul 24
4
Cyrus Harmon
2 Jul 24
144
Notice of proposed sale of securities
28 Jun 24
4
MARK N LAMPERT
18 Jun 24
4
G. Walmsley Graham
18 Jun 24
4
Sandra Horning
18 Jun 24
4
ANDREW RAPPAPORT
18 Jun 24
4
Cyrus Harmon
18 Jun 24
4
Yi Larson
18 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.72 mm | 33.72 mm | 33.72 mm | 33.72 mm | 33.72 mm | 33.72 mm |
Cash burn (monthly) | 11.61 mm | 599.83 k | 11.45 mm | 9.14 mm | 7.83 mm | 7.24 mm |
Cash used (since last report) | 44.88 mm | 2.32 mm | 44.26 mm | 35.35 mm | 30.29 mm | 27.98 mm |
Cash remaining | -11.16 mm | 31.40 mm | -10.54 mm | -1.63 mm | 3.43 mm | 5.74 mm |
Runway (months of cash) | -1.0 | 52.3 | -0.9 | -0.2 | 0.4 | 0.8 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 122 |
Opened positions | 62 |
Closed positions | 13 |
Increased positions | 25 |
Reduced positions | 20 |
13F shares | Current |
---|---|
Total value | 624.79 bn |
Total shares | 64.53 mm |
Total puts | 41.30 k |
Total calls | 55.00 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 9.14 mm | $109.36 mm |
BVF | 9.14 mm | $103.42 bn |
Paradigm Biocapital Advisors | 7.90 mm | $89.47 bn |
Logos Global Management | 4.38 mm | $49.63 bn |
Deep Track Capital | 3.23 mm | $36.51 bn |
BLK Blackrock | 3.22 mm | $36.41 bn |
STT State Street | 3.18 mm | $35.98 bn |
Vanguard | 2.41 mm | $27.26 bn |
MPM Oncology Impact Management | 1.95 mm | $22.12 bn |
Dimensional Fund Advisors | 1.94 mm | $21.92 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jul 24 | Cyrus Harmon | Common Stock | Sell | Dispose S | No | Yes | 12.26 | 5,000 | 61.30 k | 756,283 |
28 Jun 24 | Cyrus Harmon | Common Stock | Sell | Dispose S | No | Yes | 10.77 | 20,000 | 215.40 k | 761,283 |
14 Jun 24 | Graham G. Walmsley | Stock Option Common Stock | Grant | Acquire A | No | No | 12.36 | 23,000 | 284.28 k | 23,000 |
14 Jun 24 | Horning Sandra | Stock Option Common Stock | Grant | Acquire A | No | No | 12.36 | 23,000 | 284.28 k | 23,000 |
14 Jun 24 | Cyrus Harmon | Stock Option Common Stock | Grant | Acquire A | No | No | 12.36 | 23,000 | 284.28 k | 23,000 |
News
12 Health Care Stocks Moving In Tuesday's Intraday Session
4 Jun 24
HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
4 Jun 24
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
3 Jun 24
12 Health Care Stocks Moving In Monday's Intraday Session
3 Jun 24
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
3 Jun 24
Press releases
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Jun 24
Olema Oncology to Participate in Upcoming Investor Conferences in June
28 May 24
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
15 May 24
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
8 May 24
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
8 May 24